Loading company…
Voronoi researches and develops drugs, including protein degraders and kinase inhibitors.
Based in Incheon, South Korea, Voronoi researches and develops drugs, including target protein degraders and kinase inhibitors for difficult-to-treat and rare diseases. Its portfolio includes candidates targeting EGFR, PDGF, KRAS, LRRK2, and RET, and the company operates the AI-based Voronomics drug modeling platform. In June 2022, Voronoi raised KRW 52 billion in an IPO on KOSDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in